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Abstract
 .Phosducin-like protein PhLP and phosducin are highly homologous proteins that interact with the bg subunits of
guanine nucleotide binding proteins. While phosducin has a well-characterized role in retinal signal transduction, PhLP
function remains unclear. To further understand the function of PhLP, we have examined other potential protein:protein
interactions with PhLP using the yeast two-hybrid system. PhLP was found to interact with a mouse homologue of the yeast
SUG1, a subunit of the 26S proteasome which may also indirectly modulate transcription. This interaction was further
confirmed by an in vitro binding assay and co-immunoprecipitation of the two proteins in overexpression studies. Inhibition
of proteasome function by lactacystin led to accumulation of high molecular weight, ubiquitin-immunoreactive protein
precipitated by PhLP antiserum. We suggest that PhLPrSUG1 interaction may target PhLP for proteasomal degradation.
q 1998 Elsevier Science B.V.
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1. Introduction
 .Phosducin-like protein PhLP is the product of a
widely expressed gene first isolated by subtractive
w xcloning of ethanol-responsive genes 1 . Different
splice variants of the gene have been isolated which
Abbreviations: GA, Gal4 activation domain; GB, Gal4 DNA-
binding domain; G protein, heterotrimeric GTP-binding protein;
GST, glutathione S-transferase; HA, hemagglutinin; mSUG1,
mouse homologue of the yeast SUG1 protein; PhLP, phosducin-
like protein; PhLP , phosducin-like protein, short form; PCR,S
polymerase chain reaction; SDS, sodium dodecyl sulfate
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potentially generate two forms of the protein: PhLP
 .  .long PhLP and PhLP short PhLP , a truncatedS
form of PhLP missing the first 83 N-terminal amino
w xacids 1 . PhLP has a high degree of protein sequence
homology to phosducin, a cytosolic phosphoprotein
primarily expressed in the retina and pineal gland that
interacts with the bg subunits of guanine nucleotide
 . w xbinding proteins G proteins 2–5 . In the retina,
phosducin scavenges the bg subunits of the G pro-
 .tein transducin G bg , thus, preventing their reasso-t
 . w xciation with the a subunit of G G a 4,6 . Sincet t
phosducin has a higher affinity for G bg than doest
G a , it has been suggested that the formation of thet
phosducinrG bg complex is a major factor regulat-t
w xing photoreceptor responsiveness 7 . Phosducin also
inhibits the GTPase activity of several other G pro-
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w xteins 8 , and inhibits Gbg activation of effectors
w xsuch as adenylyl cyclase or phospholipase C 9–11 .
We and others have recently suggested that PhLP
may also act as an endogenous regulator of G pro-
w xteins 12,13 . PhLP interacts in vitro and in vivo with
w xGbg subunits 13 . In addition, Schroder and Lohse¨
have reported that PhLP inhibits several functions of
w xGbg subunits in vitro 12 .
To further characterize PhLP function, we chose to
identify other proteins which might interact with
w xPhLP using the yeast two-hybrid system 14 . PhLPS
was used to screen gene products from a mouse liver
cDNA library for PhLP-binding activity. One candi-
 .date, a mouse homologue mSUG1 of the yeast
w xSUG1 protein 15–20 , was found to be the primary
PhLP-binding protein in this assay. This interaction
was then confirmed using an in vitro binding assay
and by co-immunoprecipitation of the two proteins in
overexpression studies. Finally, we provide data sug-
gesting that PhLP interaction with mSUG1 may have
functional implications by targeting PhLP for protea-
somal degradation.
2. Materials and methods
2.1. DNA constructs
The PhLP–GAL4 and PhLP –GAL4 DNA bind-S
 .ing domain fusions PhLP–GB and PhLP –GB wereS
constructed by first amplifying the PhLP coding re-
w xgion from a full length rat PhLP cDNA clone 1
 .using polymerase chain reaction PCR , introducing
EcoRI and BamHI restriction sites in the 5X and 3X
 XPCR primers, respectively PhLP 5 primer:
5XGAATTCATGACAACCCTGGAT3X; PhLP 5XS
primer: 5X GAATTCATGGAGCGGCTGATC3X ;
PhLPr PhLP 3X primer: 5XGGATCCATTATCAGT-S
X.TCAATC3 . The fragments were then ligated into
 .vector pGBT9 Clontech between EcoRI and BamHI
sites and the constructs were transformed into XL1-
 .blue E. coli cells Stratagene .
 .A glutathione S-transferase GST qmSUG1 fu-
sion construct was obtained by inserting the full
length mSUG1 coding region in-frame at the car-
boxyl-terminus of GST. The mSUG1 coding se-
quence, which contains an internal EcoRI site, was
isolated by partial EcoRI digestion of a mSUG1
cDNA clone obtained in the two-hybrid library screen.
This fragment contains the full length mSUG1 coding
region and 15 bases of the 5X-untranslated region
which codes in-frame for an additional five amino
 .acids RERGK upstream of the initiator methionine.
The mSUG1 fragment was ligated into EcoRI-di-
 .gested pGEX-4T-1 Pharmacia Biotech , and the liga-
tion product was transformed into BL21 E. coli cells,
a protease-deficient E. coli strain Pharmacia
.Biotech .
 .A hemagglutinin HA epitope-tagged PhLP ex-
pression vector was generated as described previ-
w x  .ously 13 . Similarly, this HA epitope YDVPDYAS
was also fused to the carboxyl-terminus of mSUG1.
The mSUG1 coding region was amplified by PCR
using primers containing BamHI and EcoRI restric-
X X  Xtion sites at the 5 and 3 ends, respectively 5
primer: 5XGGATCCATGGCGCTTGATGGG3X; 3X
X X.primer: 5 GAATTCCTTCCATAGCTTCTT3 . This
fragment was then fused in-frame, using a two-step
ligation, with the HA epitope previously inserted into
the polylinker region of pcDNA3, between BamHI
 .and EcoRI sites of the modified vector In Vitrogen
w x13 .
All constructs were verified by DNA sequence
analysis Sequenase version 2.0, United States Bio-
.chemical .
2.2. Yeast two-hybrid system
The two hybrid assay was performed using the
Matchmaker two-hybrid system essentially as de-
 .scribed by the manufacturer Clontech . A cDNA
 .library Clontech aML4000AB containing mouse
liver cDNA’s fused to the transcriptional activation
 .domain of GAL4 GA in the pGAD10 vector was
co-transformed with the PhLP –GB fusion into yeastS
strain HF7c MATa, ura3–52, his3–200, lys2–801,
ade2–101, trp1–901, leu2–3, 112, gal4–542, gal80–
 .538, LYS2::GAL1-HIS3, URA3:: GAL4 17mers -3
. 5CYC1-lacZ . Approximately 7.5=10 transformants
were plated on yHis plates and Hisq colonies were
isolated and tested for b-galactosidase activity using
a filter assay. The Hisqrb–galq cells were then
grown in qTrp media for 48 h to allow the loss of
the PhLP –GB fusion plasmid. Cells that could notS
grow in yTrp media were then used to isolate mouse
library plasmid DNA. These plasmids were re-intro-
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duced into HF7c cells and SFY526 yeast cells MATa,
ura3–52, his3–200, ade2–101, lys2–801, trp1–901,
leu2 – 3, 112, can r, gal4 – 542, gal80 – 538,
.URA3::GAL1-lacZ , in which lacZ is under the con-
trol of a different Gal4-responsive promoter than the
one in HF7c. As suggested by the manufacturer,
additional controls included testing the interaction of
library fusions with the GAL4 DNA-binding domain
 . alone GB and a human lamin C–GB fusion Clon-
.tech . Clones satisfying all genetic screening tests
were subsequently sequenced and compared to DNA
sequence databases to determine their identity or
w xsimilarity to known proteins 21 .
[ 35]2.3. GST-fusion binding to S -PhLP in ˝itro
w35 xS -PhLP was generated as described previously
w x  .1 by T3 RNA polymerase Promega in vitro tran-
scription from a XhoI cleaved, full length rat PhLP
cDNA template plasmid. PhLP–RNA was then trans-
lated in vitro with rabbit reticulocyte lysate Pro-
. w35 x  .mega in the presence of S -methionine DuPont .
The GST–mSUG1 fusion protein was produced and
purified on glutathione Sepharose-4B resin Phar-
. w xmacia exactly as described previously 13,22 . Fol-
lowing immobilization on the beads, the GST–
mSUG1 protein was washed four times in PBS and
twice in binding buffer 50 mM KHPO , pH 6.0, 1004
mM KCl, 10 mM MgCl , 10% glycerol, 1% Tween2
. w x20 20 . The fusion protein was then incubated
w35 xovernight in the same buffer containing S -PhLP
along with blocking proteins from naive BL21 cell
lysate. Following three washes with binding buffer,
the proteins were eluted with SDS sample buffer and
resolved on a 10% SDS–polyacrylamide gel. Bound
radiolabeled PhLP was detected by autoradiography
 .or phosphoimager analysis Bio-Rad . As controls,
w35 xS -PhLP binding to GST itself or endogenous
w35 x S -reticulocyte lysate proteins no added PhLP
.RNA binding to GST–mSUG1 were also tested.
2.4. Transient transfection of COS-7 cells and im-
munoprecipitation
 5 y1.COS-7 cells 3=10 cells well were seeded,
48 h before transfection, in 6-well plates in Dul-
 .becco’s modified Eagle’s medium DMEM supple-
 .mented with 10% fetal calf serum FCS . Cells were
transfected for 5 h in serum-free DMEM with plas-
mid DNA pre-mixed with lipofectAMINE Reagent
 .BRL . The total amount of DNA in all transfections
was 1.0 mg welly1 and yielded a 10% transfection
efficiency as determined by immunocytochemistry
using the 12CA5 monoclonal antibody directed
against the HA epitope Boehringer Mannheim Bio-
.  .chemicals C. Thibault, unpublished data . When
required, the empty pcDNA3 vector was used to
maintain a constant amount of DNA. The transfected
cells were incubated overnight at 378C in DMEM
containing 10% FCS. Cells were then washed twice
with ice-cold PBS and lysed in 500 ml of hypotonic
buffer 10 mM HEPES pH 7.9, 1.5 mM MgCl , 102
mM KCl, 0.5 mM dithiothreitol, 2 mgrml leupeptin,
2 mgrml aprotinin, 20 mgrml soybean trypsin in-
. y1hibitor well . Since PhLPrmSUG1 interaction was
found to be unstable in the presence of detergents, the
immunoprecipitation was conducted on the cytosolic
fraction of transfected cells. A soluble fraction was
obtained by centrifugation of a post-nuclear super-
natant at 150 000=g for 1 h at 48C and was pre-
cleared for 30 min in the presence of protein A-
 .agarose Santa Cruz Biotechnology . A polyclonal
anti-PhLP antibody was produced against a maltose
binding protein-PhLP fusion protein and affinityS
w xpurified as described previously 13 . The pre-cleared
lysate was incubated overnight at 48C with the anti-
PhLP antibody or pre-immune serum 2 mgr1.5 mlS
.of lysate , followed by protein A- agarose. Immuno-
precipitates were washed four times with hypotonic
buffer. Protein complexes were eluted in SDS sample
buffer and analyzed by Western blot using the 12CA5
anti-HA antibody.
2.5. Immunodetection of PhLP and ubiquitinated
PhLP in NG 108-15 cells
NG108-15 neuroblastoma = glioma cells were
w xgrown as described 1 in DMEM containing 10%
q  .Serum JRH Biosciences . For Western blot analy-
sis, cells were rinsed twice in ice-cold PBS and
homogenized in 10 mM Tris–HCl, 1 mM EDTA, pH
7.6. Total cell lysates were analyzed by Western blot
using affinity-purified, polyclonal anti-PhLP anti-S
w xserum 13 . For in vivo ubiquitination studies, cells at
70% confluence in 10 cm petri dishes were treated
for 6 h in culture media containing 10 mM lacta-
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 .cystin Calbiochem or the drug vehicle alone
 .DMSO . At the end of this incubation, cells were
rinsed twice in ice-cold PBS and suspended in Non-
idet P-40 lysis buffer 50 mM Tris–HCl, pH 8.0, 150
 .mM NaCl, 1% vrv Nonidet P-40, 2 mgrml apro-
tinin and leupeptin, 1 mM phenylmethylsulfonyl fluo-
.ride . After 15 min on ice, the insoluble material was
removed by centrifugation at 10 000=g for 10 min
at 48C. Immunoprecipitations were then done as above
with anti-PhLP antiserum or pre-immune serum.S
Immunoprecipitates were analyzed by Western blot
using an anti-ubiquitin monoclonal antibody Im-
.munotech .
3. Results
Using PhLP –GB as bait, a yeast two-hybrid screenS
was used to detect PhLP-interacting proteins in a
library of mouse cDNA–Gal4 activation domain fu-
sion clones. Screening of 7.5=105 transformants on
yHis media yielded 75 Hisq colonies and four of
q  .these proved to be lacZ Fig. 1 . These four clones
were sequenced and three of them were identified as
mSUG1, the mouse homologue of the yeast SUG1
w xgene 15,23 . These three clones contained the full
length coding region of mSUG1 fused in-frame with
the Gal4 DNA binding domain and their DNA se-
quence was identical to that previously reported for
 . w xmSUG1 accession aZ54219 15 . The fourth clone
was the mouse alcohol dehydrogenase accession
.aM11307 , the significance of which is currently
being studied. In addition, full length PhLP protein
 .PhLP–GB also interacted with mSUG1 in the yeast
two-hybrid system S. Barhite and M.F. Miles, un-
.published data .
The specificity of the PhLPrmSUG1 interaction
was confirmed by in vitro binding studies using a
GST pull down assay. GST–mSUG1 fusion protein,
w35 xor GST alone, was incubated with S -PhLP pro-
duced by in vitro transcriptionrtranslation of a rat
PhLP cDNA clone. Fig. 2 shows that the GST–
mSUG1 fusion protein bound a radiolabeled protein
migrating at the expected molecular weight for PhLP
Fig. 1. Identification of a PhLP-interacting protein by yeast two-hybrid screening. Mouse cDNA clones fused to the transcriptional
 .activation domain of Gal4 GA were screened using a yeast two-hybrid approach with PhLP as the bait protein coupled to the Gal4S
 . 5DNA binding domain GB . Following screening of 7.5=10 clones, 4 putative PhLP -interacting clones were identified. Positives wereS
confirmed by clonal isolation of the interacting cDNA and repeated genetic screening. Results obtained with mSUG1–GA are depicted.
Yeast cells were transformed with mSUG1–GAqGB alone, PhLP –GB or pLAM–GB. The latter is human lamin C fused to GB as anS
additional control for nonspecific binding. Growth on qLeurqTrp confirmed the presence of both plasmids in all transfections. Only
 q.  q.cells transformed with PhLP –GBqmSUG1–GA showed growth on yHis media His and b-galactosidase activity lacZ .S
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w35 xFig. 2. GST–mSUG1 binds S -PhLP. In vitro translation reac-
 .tions were programmed with no added template C or with PhLP
RNA transcribed from a full length PhLP cDNA construct using
 . w35 xT3 RNA polymerase Ph . S -labeled proteins were incubated
in vitro with GST alone or GST–mSUG1 immobilized on glu-
tathione-agarose beads. Following washing, proteins remaining
on the beads were analyzed by SDS–PAGE and autoradiography.
 .Panels depict total in vitro translation IVT products vs. those
binding to GST–mSUG1 or GST alone. Results are representa-
tive of experiments repeated twice.
on SDS–polyacrylamide gel analysis, while no de-
tectable PhLP binding was seen with GST alone.
The PhLPrmSUG1 interaction was further sub-
stantiated by co-immunoprecipitation of the complex
with an affinity purified, polyclonal anti-PhLP anti-S
body, following overexpression of the proteins in
Fig. 3. Co-immunoprecipitation of mSUG1–HA and PhLP–HA
from COS-7 cells. COS-7 cells were transfected with expression
plasmids containing mSUG1 or PhLP coupled to a HA epitope.
Cells were lysed in hypotonic media 24 h after transfection and
 .subjected to immunoprecipitation with pre-immune serum PI or
anti-PhLP polyclonal antiserum. Precipitated proteins were iden-S
tified by Western blot analysis using a monoclonal antibody
 .recognizing the HA epitope upper panel . Expression of proteins
was confirmed by Western blot analysis of cell lysates prior to
 .immunoprecipitation lower panel . The position of mSUG1–HA
and PhLP–HA are indicated. Results are representative of experi-
ments repeated twice.
 .COS-7 cells Fig. 3 . In order to facilitate the detec-
tion of the precipitated proteins, we added an HA
epitope tag onto the carboxyl-terminal end of PhLP
and mSUG1. COS-7 cells were transfected with DNA
plasmids encoding PhLP–HA, mSUG1–HA, or a
combination of both plasmids. Expression of the
proteins in COS-7 cells was monitored by Western
blot analysis using monoclonal anti-HA antibody Fig.
.3, lower panel . PhLP–HA was specifically precipi-
tated by the anti-PhLP antibody but not by theS
 .pre-immune serum Fig. 3, upper panel . In addition,
this antibody co-precipitated mSUG1–HA only when
 .co-expressed with PhLP–HA Fig. 3, upper panel .
Other SUG1-interacting proteins have been local-
ized to the proteasome, suggesting a role of SUG1 in
w xtargeting proteins for degradation 23 . Since the
Fig. 4. PhLP antiserum immunoprecipitates polyubiquitinated
protein in lactacystin-treated NG108-15 cells. NG108-15 cells
were grown in the presence or absence of lactacystin, a protea-
some inhibitor, for 6 h prior to preparation of whole cell cleared
lysates for immunoprecipitation with affinity-purified, polyclonal
 .PhLP antiserum a Ph, lanes 2 and 3 . Mock immunoprecipita-S
 .tion with pre-immune serum PI was also done on lactacystin-
 .treated cells lane 1 . Immunoprecipitates were analyzed by
SDS–polyacrylamide gel electrophoresis and Western blotting
 .using a monoclonal antibody against ubiquitin aUb . NG108-15
total cell lysates probed by Western blot analysis with the PhLPS
antiserum showed a single major band migrating at the expected
 .  .molecular weight 46 kDa for full length PhLP protein lane 4 .
( )S. Barhite et al.rBiochimica et Biophysica Acta 1402 1998 95–101100
covalent addition of polyubiquitin to proteins is a
common means used by eucaryotic cells to target
w xproteins for proteasomal degradation 24 , we exam-
ined whether PhLP was modified by polyubiquitina-
tion. For these studies, we used NG108-15 neuroblas-
toma=glioma cells which express predominantly the
full length PhLP protein as determined by Western
 .blot analysis Fig. 4, lane 4 . Following treatment of
NG108-15 cells with lactacystin, a specific inhibitor
w xof proteasome function 25,26 , PhLP protein was
immunoprecipitated from whole cell lysates. Im-
munoprecipitates were analyzed by SDS–polyacryl-
amide gel electrophoresis followed by Western blot-
ting with antiserum against ubiquitin. PhLP immuno-
precipitates from lactacystin-treated cells showed a
dramatic increase in ubiquitin-immunoreactive mate-
rial migrating diffusely at molecular weights extend-
ing well above the 46 kDa expected for unmodified
 .PhLP Fig. 4, lane 3 . A small amount of ubiquitin
immunoreactive material was seen in cells without
lactacystin treatment or following immunoprecipita-
 .tion with pre-immune serum Fig. 4, lanes 1 and 2 .
This data suggests that PhLP is extensively modified
by ubiquitination.
4. Discussion
In the present study, we identified interactions
between the mouse SUG1 protein and PhLP using
three independent assays. Repeated isolation of
mSUG1 in the yeast two-hybrid system, in vitro
binding of PhLP to GST–mSUG1 and co-immuno-
precipitation of PhLP and SUG1 from COS-7 cells,
together, provide strong evidence that these two pro-
teins may have a biologically relevant interaction.
Since PhLP is known to interact with the b-sub-
w xunits of heterotrimeric G proteins 13 , it might seem
somewhat surprising that the yeast two-hybrid analy-
sis did not isolate Gb. However, Gb is generally not
thought capable of forming a stable protein configu-
ration without the obligate partner, Gg . Thus,
PhLP –GB interaction with Gbg would have re-S
quired a trimeric protein complex, an extremely un-
likely event under the transfection conditions used for
the two-hybrid screening unless endogenous yeast Gg
were to substitute for the mouse homologue. It is
likely that formation of such a cross-species complex
would be much less stable, particularly given the
fusion protein configurations for PhLP and Gb.
The function of SUG1 is not completely under-
stood but it has been implicated in two different
cellular processes. A role as a mediator in transcrip-
tional regulation has been suggested since SUG1 has
been found in the yeast RNA polymerase II complex
w x27 and been shown to interact with several known
w xyeast enhancer binding proteins 20,28 . Mammalian
homologues of SUG1, termed TRIP, mSUG1 and
FZA-B, have been shown to interact with nuclear
w x w xhormone receptors 15,19 and c-fos 23 , respec-
tively. Wang et al. also reported that c-fos co-local-
w xizes with mSUG1 in proteasomes 23 . Similarly,
TRIP was later co-purified with the proteasome see
w x.correction to Ref. 20 . It was thus suggested that
SUG1 may regulate transcription either directly as a
transcriptional mediator, or indirectly, via targeted
w xdegradation of transcriptional proteins 15,23 . In both
yeast and mammalian cells, SUG1 has also been
shown to be a component of the 26S proteasome
w x29–31 . SUG1 is homologous to several other con-
served ATPase domain proteins also present in the
w x26S proteasome 32 . These ATPases have been sug-
gested to play a regulatory role in proteasome func-
tion, or possibly serve to target specific proteins for
w xproteasome degradation 32 .
Thus, PhLPrSUG1 interaction might serve to di-
rect PhLP for proteasomal degradation. Our initial
studies support this idea, showing that polyubiquiti-
nated protein precipitated by PhLP antiserum accu-
mulates when proteasome function is inhibited by
lactacystin. Further studies will establish whether
SUG1 indeed targets PhLP for proteasomal degrada-
tion and whether PhLPrSUG1 interactions might
modulate Gbg signaling.
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